Patricia Yotnda

Title: Patricia Yotnda: Innovator in Immunogenic Peptides

Introduction

Patricia Yotnda is a notable inventor based in Houston, TX (US). She has made significant contributions to the field of immunology, particularly in the development of therapeutic vaccines. With a total of 2 patents, her work focuses on optimizing immunogenic peptides for the treatment and prevention of leukemia in humans.

Latest Patents

One of her latest patents is titled "Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof." This invention concerns the optimization of the wild R9M peptide and its application for therapeutic and preventive vaccination against leukemia. The invention specifically addresses mutated immunogenic peptides derived from the human TEL/AML1 fusion protein, which includes the wild R9M peptide sequence Arg-Ile-Ala-Glu-Czs-Ile-Leu-Gly-Met. Additionally, it encompasses polynucleotides coding for these mutated peptides, cellular expression vectors, and antibodies that can bind to the peptides or polynucleotides. The invention aims to prepare vaccines and anti-tumoral medicines, enhancing the immune response in humans both in vitro and in vivo.

Career Highlights

Patricia has worked with prestigious organizations such as Institut Pasteur and Assistance Publique-Hopitaux De Paris. Her experience in these institutions has allowed her to collaborate with leading experts in the field of immunology and contribute to groundbreaking research.

Collaborations

Some of her notable coworkers include Pierre Rohrlich and Etienne Vilmer. Their collaborative efforts have further advanced the research and development of immunogenic peptides.

Conclusion

Patricia Yotnda's innovative work in the field of immunogenic peptides has the potential to significantly impact therapeutic vaccination against leukemia. Her contributions reflect her dedication to advancing medical science and improving patient outcomes.